In 2018, the Therapeutic Goods Administration (TGA) approved two products to be used for opioid addiction.
Buvidal® (buprenorphine depot injection) is approved as the maintenance treatment of opioid dependence; while Nyoxid® (naloxone nasal spray) is approved as an antidote for opioid overdose.
The availability of these products on the Australian market will be a positive step to optimise treatment options and access to those who use opioids.
These two products will now be considered by the Pharmaceutical Benefits Advisory Committee (PBAC) for the Pharmaceutical Benefits Scheme (PBS) in March 2019.
Don’t miss the chance to hear from the most recognisable and influential people in the sector, with the opportunity to ask questions and learn more about the treatment of addiction in this country.
Other topics include:
- Hepatitis C Treatment – how things have changed
- Caught in the drug court
- Legal and lethal
When: 9:00am to 12:30pm, Sunday 10 March 2019
Where: Meeting Room 9, GCCEC
Download the flyer below for more details.